| Literature DB >> 35407349 |
Thais S M Lima1,2, Wanderson Souza1,2, Luths R O Geaquinto1,2, Priscila L Sanches1,3, Ewa L Stepień4, João Meneses5, Eli Fernández-de Gortari5, Nicole Meisner-Kober6, Martin Himly6, José M Granjeiro1,2,3,7, Ana R Ribeiro2,5.
Abstract
The progressively increasing use of nanomaterials (NMs) has awakened issues related to nanosafety and its potential toxic effects on human health. Emerging studies suggest that NMs alter cell communication by reshaping and altering the secretion of extracellular vesicles (EVs), leading to dysfunction in recipient cells. However, there is limited understanding of how the physicochemical characteristics of NMs alter the EV content and their consequent physiological functions. Therefore, this review explored the relevance of EVs in the nanotoxicology field. The current state of the art on how EVs are modulated by NM exposure and the possible regulation and modulation of signaling pathways and physiological responses were assessed in detail. This review followed the manual for reviewers produced by The Joanna Brigs Institute for Scoping Reviews and the PRISMA extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. The research question, "Do NMs modulate cellular responses mediated by EVs?" was analyzed following the PECO model (P (Population) = EVs, E (Exposure) = NMs, C (Comparator) = EVs without exposure to NMs, O (Outcome) = Cellular responses/change in EVs) to help methodologically assess the association between exposure and outcome. For each theme in the PECO acronym, keywords were defined, organized, and researched in PubMed, Science Direct, Scopus, Web of Science, EMBASE, and Cochrane databases, up to 30 September 2021. In vitro, in vivo, ex vivo, and clinical studies that analyzed the effect of NMs on EV biogenesis, cargo, and cellular responses were included in the analysis. The methodological quality assessment was conducted using the ToxRTool, ARRIVE guideline, Newcastle Ottawa and the EV-TRACK platform. The search in the referred databases identified 2944 articles. After applying the eligibility criteria and two-step screening, 18 articles were included in the final review. We observed that depending on the concentration and physicochemical characteristics, specific NMs promote a significant increase in EV secretion as well as changes in their cargo, especially regarding the expression of proteins and miRNAs, which, in turn, were involved in biological processes that included cell communication, angiogenesis, and activation of the immune response, etc. Although further studies are necessary, this work suggests that molecular investigations on EVs induced by NM exposure may become a potential tool for toxicological studies since they are widely accessible biomarkers that may form a bridge between NM exposure and the cellular response and pathological outcome.Entities:
Keywords: cell communication; extracellular vesicles; nanomaterials; nanotoxicology
Year: 2022 PMID: 35407349 PMCID: PMC9000848 DOI: 10.3390/nano12071231
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Definition of key terms based on the PECO strategy [30].
| Acronym | Definition | Description |
|---|---|---|
| P | Population | Extracellular vesicles |
| E | Exposure | Nanomaterials |
| C | Comparison | Extracellular vesicles without nanomaterials exposure |
| O | Outcome | Cellular response |
Figure 1(A) PRISMA flow diagram applied in this ScR, co-occurrence network of the most frequently used keywords in the (B) 2944 unique results and (C) 18 ultimately selected articles. Each color suggests a set of keywords shared among the analyzed articles.
Physicochemical characteristics of NMs, exposure conditions, and biological effects observed in the respective experimental models.
| Reference | Nanomaterial | Exposure Conditions | Biological Effects 4 | ||||
|---|---|---|---|---|---|---|---|
| Type 1 | Size 2 | Morphology/Crystalline Structure | Purity 3 | Z Potential | |||
| [ | PEI-SPION NPs | 15 nm | - | - | Low density: 4.5 mV | Immersion CM | In vitro Human HMVECs: |
| [ | MIONs | - | - | LPS < 0.25 EU ml−1 | - | Respiratory exposure (Intratracheal instillation) | In vivo Mouse BALB/c: |
| [ | SiO2 NPs | 10–20 nm | - | ≈ 99.5% | - | Immersion CM | In vitro: Human THP-1 |
| [ | Au NPs | P: 20 nm | - | - | - | Immersion CM | In vitro Human PBMCs: |
| [ | SWNCTs | 200–1000 nm | Fiber-like | >95% | −44.1 mV (pH 12); | Immersion CM | In vitro Mouse PMQ: |
| [ | TiO2 NPs | P: 21 nm; | - | LPS: NPs < 50 pg/mL; Culture media < 5 pg/mL) | −12.2 ± 0.25 mV | Immersion CM | In vitro Human PBMC: |
| [ | Fe3O4 NPs | 100 nm | - | - | - | Immersion CM | In vitro: Human BMSCs: |
| [ | MIONs | P: 43 nm | Cubic | LPS < 0.25 EU ml−1) | - | Respiratory exposure (Intratracheal instillation) | In vivo Mouse BALB/c: |
| [ | CaP | 1.84 ± 0.48 μm | Spherical or oval | - | −2.49 mV | Immersion CM | In vitro Mouse RAW264.7: |
| [ | Au NPs | 5, 20, 80 nm | Spherical | - | AuNPs-5: −22.01 ± 1.81 mV, AuNPs-20: −32.17 ± 2.19, | Immersion CM | In vitro Mouse mESCs: |
| [ | Pt NPs | 40–50 nm | Spherical, triangular, oval, and rod-shaped | - | Immersion CM | In vitro Human A549 monolayer culture: | |
| [ | Pd NPs | ~20 nm | Spherical | - | - | Immersion CM | In vitro Human THP-1 Monolayer culture: |
| [ | Fe3O4 NPs | 8, 15, 30 nm | Spherical | 8 nm (99.9%), 15–20 nm (99.5%) and 20–30 nm (99.0%) | - | Immersion CM | In vitro Human iNPCs Cortical spheroids culture: |
| [ | POSS NPs | 3–5 nm | Spherical | - | - | Immersion culture media | In vitro: Human HUVECs: |
| [ | nHAp | <100 nm | Rod-like | 97% | - | Immersion CM | In vitro Mice C57BL/6 VSMCs: |
| [ | s-GO | 50–500 nm | - | LPS free | −55.9 ± 1.4 mV | Immersion CM | In vitro Rats Wistar Astrocytes: |
| [ | PAMAM | G2:3 nm | - | - | G2-NH2: 19.8 mV; | Immersion CM | In vitro Human HUVECs: |
| [ | NCs | Ag NCs: 1.3 nm; Fe3O4 | - | - | - | Immersion CM | In vitro Human L02: |
1 AuNPs (Gold nanoparticles), AgNO3 NCs (Silver NCs), CaP (calcium phosphate particles), COOH-terminated (anionic), Fe3O4 NCs (Iron oxide NCs), Fe3O4NPs (Magnetic iron oxide nanoparticles), MIONs (Magnetic iron oxide nanoparticles), NCs (Silver and Iron oxide nanoclusters), nHAp (Nano-hydroxyapatite), NH2-terminated (cationic), NPs (Nanoparticles), PAMAM (polyamidoamine dendrimers), PEI-SPION NPs (NPs superparamagnetic iron oxide NPs associated with NPs polyethyleneimine), Pd NPs (Palladium nanoparticles). POSS NPs (Polyhedral oligomeric silsesquioxane nanoparticles), Pt NPs (Platinum nanoparticles), s-GO (Small graphene-oxide nano-flakes), SiO2NPs (Silicon dioxide nanoparticles), SWNCTs (acid-oxidized single-walled carbon nanotubes), TiO2 NPs (Commercial titanium dioxide), ZnO (Commercial zinc oxide). 2 P (Primary), CM (Culture Medium). 3 LPS (Endotoxin contamination). 4 ↑ ((Increase, induction), ↓ ((Decrease, loss), AChE (Acetylcholinesterase), ALP (Alkaline phosphatase), Ang (angiopoietin), A549 (human lung epithelial adenocarcinoma cancer cells), BMSCs (Bone mesenchymal stem cells), Cas (Caspase), CAT (Catalase), DNA (Deoxyribonucleic acid), ER (Endoplasmic reticulum), FGF (fibroblast growth factor), GSH (Glutathione), GST (Glutathione S-transferases), GPx (Glutathione peroxidase), HepG2 (Human hepatocellular carcinoma), HMVECs (human microvascular endothelial cells), HUVECs (Human umbilical vein endothelial cells), IC50 (Half maximal inhibitory concentration), IL-4 (Interleukin-4), iNPCs (Neural progenitor cell), LDH (Lactate dehydrogenase), LHP (Lipid hydroperoxides), LOEC (Lowest observed effect concentration), L02 (Human embryonic liver cell), RAW264.7 (Macrophage-like), MDA (Malondialdehyde), MDDC (Monocyte-derived dendritic cells), NO (Nitric Oxid), OPN (Osteopontin), OVA (Ovalbumin-sensitized), mESCs (mouse embryonic stem cells), PBMC (Primary human peripheral blood mononuclear cells), PCC (Protein carbonylation content), PMQ (non-activated primary mouse peritoneal macrophages), ROS (Reactive oxygen species), Runx2 (Runt-related transcription factor 2), Tc (T cytotoxic cell), Th (T-helper cell), Th1 (T-helper cell type 1), Th2 (T-helper cell type), IFN-γ (Interferon-gamma), THP-1 (Human leukemia monocyte-like), TRX (Thioredoxin), TGF-β (transforming growth factor beta), VEGF (Vascular endothelial growth factor), VEGFR-2 (VEGF receptors), VEGF-A (VEGFR-2 ligand), VSMCs (primary mice vascular smooth muscle cells).
Overview of the effects of NM exposure on EVs secretion and consequent biological outcomes.
| Reference | Nanomaterials 1 | Biological Origin and Fluid Collection 2 | Isolation and Characterization 3 | EV Nomenclature and Size 4 | Ev Enriched and not Enriched Markers 5 | Biological Outcomes 6 |
|---|---|---|---|---|---|---|
| [ | PEI-SPION NPs | HMVECs; | HSC, MS; | EVs; | - | ↑ EVs associated with apoptotic cell; |
| [ | MIONs | Mouse | Centrifugation and ultracentrifugation; | Exosomes | - | ↑ Exosome biogenesis |
| [ | SiO2 NPs | IMR-90 and THP-1; | Ultracentrifugation; | Exosomes | - | ↑ Exosome biogenesis; |
| [ | Au NPs | PBMCs | Centrifugation and ultracentrifugation. | Exosomes | TSG101, CD9, and CD81 | ↑ Exosome size and refractive index; |
| [ | SWNCTs | PMQ; | TEM, SEM, RAMAN | Exosomes; | - | ↑ Exosome biogenesis on the surface of macrophages; |
| [ | TiO2 NPs | PBMC and MDDC; | Ultracentrifugation, | Exosomes; | CD81, CD63, CD61, CD86, CD95/FasL MHCI and MHCII | No alterations in exosome secretion, morphology, size, number, or protein cargo |
| [ | Fe3O4, NPs | BMSCs | Centrifugation and ultracentrifugation | Exosomes | CD9, CD63, CD81, TSG101 | ↑ Exosome biogenesis. |
| [ | MIONs | Mouse | Centrifugation and ultracentrifugation; | Exosomes | TSG101 | No morphological or size changes of exosomes |
| [ | CaP | RAW264.7 and THP-1 | Total Exosomes Isolation Kit | Exosomes: | CD9, LAMP-1 | ↑ Exosome biogenesis. |
| [ | Au NPs | mESCs; | Ultracentrifugation and filtration | EVs | CD63, HSP70, and Flotilina-1 | EVs-5: ↑ The rigidity of EVs, differentially expressed protein profile, and cellular uptake. |
| [ | Pt NPs | A549 | Differential centrifugation and ExoQuick; | Exosomes | TSG101, CD81, CD63, CD9 | ↑ Exosome biogenesis |
| [ | Pd NPs | THP1; | Differential ultracentrifugation and ExoQuickTM; | Exosomes | TSG101, CD9, CD63 and CD81 | ↑ Exosome biogenesis. |
| [ | Fe3O4 NPs | iNPs; | Differential ultracentrifugation and PEG-based method; | EVs | CD63, CD81, Alix, TSG101, Syntenin1, ADAM10, RAB27b, and Syndecan | 8 and 15 nm: ↑ EV biogenesis. |
| [ | POSS NPs | HUVECs; | Exo-spin™ kit and centrifugation | Exosomes | CD63 | ↑ Exosome biogenesis |
| [ | nHAp | VSMCs; | Centrifugation and ultracentrifugation | Exosomes | Alix, TSG101, and CD9 | ↑ Exosome biogenesis. |
| [ | s-GO | Astrocytes; | Centrifugation | MVs | Flotillin-1 | ↑ MV biogenesis; |
| [ | PAMAM | HUVECs | Centrifugation | EVs | - | ↑ EV biogenesis; |
| [ | NCs | HepG2; | Centrifugation, filtration, and ultracentrifugation | Exosomes | - | No changes in exosome morphology or size |
1 A549 (human lung epithelial adenocarcinoma cancer cells), BMSCs (Bone mesenchymal stem cells), Cas (Caspase), CAT (Catalase), HepG2 (Human hepatocellular carcinoma), HMVECs (human microvascular endothelial cells), HUVECs (Human umbilical vein endothelial cells), iNPCs (Neural progenitor cell), LDH (Lactate dehydrogenase), L02 (Human embryonic liver cell), RAW264.7 (Macrophage-like), MDDC (Monocyte-derived dendritic cells), OVA (Ovalbumin-sensitized), mESCs (mouse embryonic stem cells), PBMC (Primary human peripheral blood mononuclear cells), PMQ (non-activated primary mouse peritoneal macrophages), Tc (T cytotoxic cell), Th (T-helper cell), Th1 (T-helper cell type 1), Th2 (T-helper cell type), THP-1 (Human leukemia monocyte-like), VSMCs (primary mice vascular smooth muscle cells). 2 AuNPs (Gold nanoparticles), AgNO3 NCs (Silver NCs), CaP (calcium phosphate particles), COOH-terminated (anionic), Fe3O4 NCs (Iron oxide NCs), Fe3O4NPs (Magnetic iron oxide nanoparticles), MIONs (Magnetic iron oxide nanoparticles), NCs (Silver and Iron oxide nanoclusters), nHAp (Nano-hydroxyapatite), NH2-terminated (cationic), NPs (Nanoparticles), PAMAM (polyamidoamine dendrimers), PEI-SPION NPs (NPs superparamagnetic iron oxide NPs associated with NPs polyethyleneimine), Pd NPs (Palladium nanoparticles). POSS NPs (Polyhedral oligomeric silsesquioxane nanoparticles), Pt NPs (Platinum nanoparticles), s-GO (Small graphene-oxide nano-flakes), SiO2NPs (Silicon dioxide nanoparticles), SWNCTs (acid-oxidized single-walled carbon nanotubes), TiO2 NPs (Commercial titanium dioxide), ZnO (Commercial zinc oxide). 3 UC (Ultracentrifugation), TEM (Transmission electron microscopy), NTA (Nanoparticle Tracking Analysis), SEM (Scanning Electron Microscopy), FC (Flow cytometry), HSC (High-speed centrifugation), MS (Magnetic separation), CLSM (Confocal Laser Scanning Microscopy), WB (Western blot), AFM (Atomic force microscopy), UVRR (UV Resonant Raman), FTIR-ATR (Attenuated Total Reflection Fourier Transform Infrared), AchE (Acetylcholinesterase), EDS (Energy-Dispersive X-ray Spectroscopy), SP-ICP-MS (Single Particle Inductively Coupled Plasma Mass Spectrometry), ICP-OES (Inductively Coupled Plasma Optical Emission Spectrometry), FACS (Fluorescence-activated cell scanning), QCM-D (Quartz crystal microbalance with dissipation), LC-MS/MS (Liquid chromatography-tandem mass spectrometry), FP (Fluorescence polarization), BCA (Bicinchoninic acid assay kit), PEG (Polyethylene glycol), RT-PCR (Reverse transcription polymerase chain reaction), qRT-PCR (Quantitative Reverse Transcription-Polymerase Chain Reaction); 4 MVBs (Multivesicular bodies), EVs (Extracellular vesicles), MVs (Microvesicles), EVs-5 (Extracellular vesicles); 5 CD (Tetraspanin), TSG101 (Tumor susceptibility gene 101); 6 CD (Tetraspanin), TSG101 (Tumor susceptibility gene 101), IL (Interleukin), PS+ (phosphatidyl serine-positive), PSCs (Heterogeneous postsynaptic currents), U87 (Human primary glioblastoma), Ca (Calcium), BALF (Bronchoalveolar lavage fluid), iDCs (Immature dendritic cells), APCs (Antigen-presenting cells), MHC (Major histocompatibility complex), AM φ (Alveolar macrophages), DC1 (cytokine DC subset 1), Erk (Extracellular regulated protein kinase), HSP70 (Heat shock protein 70).
Figure 2Schematic representation of the overall effect of NMs on secreted EVs.
Figure 3(A) Detailed network of the 18 articles that met all the eligibility criteria. The dashed rectangle highlights article [41], summarized in Table 3. In short, [41] used MIONs with a size ranging between 10 and 100 nm. MIONs were exposed to a bronchoalveolar lavage fluid (BALF) extracted from mice, inducing an increase of EVs biogenesis. EVs, with a size between 30 and 100 nm and enriched in TSG101, induced iDC maturation, immune-system activation, and T-cell differentiation. Overall, and regarding all experimental conditions, exosome morphology and size were not affected. (B) Most relevant biological outcomes and their connections among the 18 analyzed articles. For instance, despite using different experimental conditions, 15 out of 18 articles pointed to increased EV biogenesis as one of their outcomes. Regarding the duplicated author’s nomenclature, ZhuA, ZhuB, GurunathanA, and GurunathanB correspond to [22,41,44,45], respectively.
Figure 4Cell exposure to NMs induces EV biogenesis and modulations in various biological activities: elimination of NMs; impact on cellular functions; alterations in cell communication; immunomodulation, inflammation, and immune activation; and angiogenesis and healing.